COMPANY PROFILE

Meves Pharmaceuticals

Explore full profile

Nucleoside-based therapies for severe genetic mitochondrial diseases

New York City, United StatesFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2018

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Meves Pharmaceuticals

Meves Pharmaceuticals was a biotechnology firm established in 2016 and based in New York City. The company focused on developing targeted, nucleoside-based therapies to treat mitochondrial DNA (mtDNA) depletion disorders, a class of severe genetic diseases. Its primary therapeutic focus was on creating a treatment for patients with Thymidine Kinase 2 (TK2) deficiency, a condition that leads to muscle and skeletal weakening.

In March 2018, Meves Pharmaceuticals secured $10.9 million in a Series A funding round. The company operated within the biotechnology and pharmaceutical sectors, aiming to provide treatments for rare and serious disorders. However, according to market data, the company ceased operations around August 2018 and is now considered deadpooled.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: New York City, United States
Open positions: None listed
Dealroom signal: 16.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Rare Diseases, Hard Tech, DT and LS, science-based
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Mar 2018	$11M	$44M	Undisclosed	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Meves Pharmaceuticals website traffic

Latest recorded traffic for Meves Pharmaceuticals is 0 monthly website visits.

Latest monthly visits0

Monthly website visitsJun 2018–Apr 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSuzhou Huitherapy Biomedical Technology a high-tech enterprise engaged in the industrialization of comprehensively providing nucleic acid drugs	China	Operational	—	$41M	$138M
HGHemu GeneA gene therapy technology developer	Ningde City, China	Operational
MOMonoclonalsDevelops novel monoclonal antibodies for rapid tests which diagnose diseases, specifically for resource poor areas	Ellsworth, United States	Operational
ATAlamab TherapeuticsClinical Trial Approval in Australia	Princeton, United States	Operational
FUFuturedMeFuturedMe Inc.- A pioneer in the science of using novel protein degradation CANDDYTM Platform towards “No Patients without Medicine”-	Tokyo, Japan	Operational
WTWings TherapeuticsTherapeutics for rare genetic blistering skin diseases	Berkeley, United States	Operational
CECellAxiaSpecialized in the research, manufacturing and sales of products such as new drugs and regenerative medicine	Tokyo, Japan	Operational
SOSovargenLeading the way in RNA therapies for brain diseases	Daejeon, South Korea	Operational